Full Press Release Details
Phase II Clinical Study of Elenbecestat Demonstrates Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months.
BIIB
Phase II Clinical Study of Elenbecestat Demonstrates Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months
Key Takeaway: Phase II Clinical Study of Elenbecestat Demonstrates Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months